Central memory phenotype drives success of checkpoint inhibition in combination with CAR T cells
Open Access
- 25 April 2020
- journal article
- research article
- Published by Wiley in Molecular Carcinogenesis
- Vol. 59 (7) , 724-735
Abstract
The immunosuppressive microenvironment in solid tumors is thought to form a barrier to the entry and efficacy of cell‐based therapies such as chimeric antigen receptor (CAR) T cells. Combining CAR T cell therapy with checkpoint inhibitors has been demonstrated to oppose immune escape mechanisms in solid tumors and augment antitumor efficacy. We evaluated PD‐1/PD‐L1 signaling capacity and the impact of an inhibitor of this checkpoint axis in an in vitro system for cancer cell challenge, the coculture of L1CAM‐specific CAR T cells with neuroblastoma cell lines. Fluorescence‐activated cell sorting‐based analyses and luciferase reporter assays were used to assess PD‐1/PD‐L1 expression on CAR T and tumor cells as well as CAR T cell ability to kill neuroblastoma cells. Coculturing neuroblastoma cell lines with L1CAM‐CAR T cells upregulated PD‐L1 expression on neuroblastoma cells, confirming adaptive immune resistance. Exposure to neuroblastoma cells also upregulated the expression of the PD‐1/PD‐L1 axis in CAR T cells. The checkpoint inhibitor, nivolumab, enhanced L1CAM‐CAR T cell‐directed killing. However, nivolumab‐enhanced L1CAM‐CAR T cell killing did not strictly correlate with PD‐L1 expression on neuroblastoma cells. In fact, checkpoint inhibitor success relied on strong PD‐1/PD‐L1 axis expression in the CAR T cells, which in turn depended on costimulatory domains within the CAR construct, and more importantly, on the subset of T cells selected for CAR T cell generation. Thus, T cell subset selection for CAR T cell generation and CAR T cell prescreening for PD‐1/PD‐L1 expression could help determine when combination therapy with checkpoint inhibitors could improve treatment efficacy.Keywords
Funding Information
- Wilhelm Sander-Stiftung (2018.011.1)
- Deutsche Forschungsgemeinschaft (#398299703)
- Else Kröner-Fresenius-Stiftung (#2017_A51)
This publication has 46 references indexed in Scilit:
- Multiplex Genome Editing to Generate Universal CAR T Cells Resistant to PD1 InhibitionClinical Cancer Research, 2017
- Enhancement of PSMA-Directed CAR Adoptive Immunotherapy by PD-1/PD-L1 BlockadeMolecular Therapy-Oncolytics, 2017
- The Principles of Engineering Immune Cells to Treat CancerCell, 2017
- GD2-specific CAR T Cells Undergo Potent Activation and Deletion Following Antigen Encounter but can be Protected From Activation-induced Cell Death by PD-1 BlockadeMolecular Therapy, 2016
- A Chimeric Switch-Receptor Targeting PD1 Augments the Efficacy of Second-Generation CAR T Cells in Advanced Solid TumorsCancer Research, 2016
- Multifactorial T-cell Hypofunction That Is Reversible Can Limit the Efficacy of Chimeric Antigen Receptor–Transduced Human T cells in Solid TumorsClinical Cancer Research, 2014
- Programmed cell death 1 forms negative costimulatory microclusters that directly inhibit T cell receptor signaling by recruiting phosphatase SHP2Journal of Experimental Medicine, 2012
- PD-1 and Its Ligands in Tolerance and ImmunityAnnual Review of Immunology, 2008
- CTLA-4 and PD-1 Receptors Inhibit T-Cell Activation by Distinct MechanismsMolecular and Cellular Biology, 2005
- PD‐1 inhibits T‐cell receptor induced phosphorylation of the ZAP70/CD3ζ signalosome and downstream signaling to PKCθFEBS Letters, 2004